{
    "organizations": [],
    "uuid": "27b60b6e1e8df707b3ad4d8e0b48a7808127d98b",
    "author": "",
    "url": "https://www.reuters.com/article/brief-gsk-says-viiv-healthcare-reports-p/brief-gsk-says-viiv-healthcare-reports-positive-dolutegravir-data-idUSFWN1QN0S9",
    "ord_in_thread": 0,
    "title": "BRIEF-GSK Says ViiV Healthcare Reports Positive Dolutegravir Data",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 5 (Reuters) - Glaxosmithkline Plc:\n* GLAXOSMITHKLINE PLC - VIIV HEALTHCARE ANNOUNCES POSITIVE NEW DOLUTEGRAVIR DATA FOR TREATMENT OF PEOPLE LIVING WITH HIV CO-INFECTED WITH TUBERCULOSIS\n* GLAXOSMITHKLINE PLC - DOLUTEGRAVIR WHEN ADMINISTERED AT 50MG TWICE-DAILY WITH DUAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, WAS EFFECTIVE\n* GLAXOSMITHKLINE PLC - DOLUTEGRAVIR WAS WELL-TOLERATED IN HIV/TB CO-INFECTED ADULTS RECEIVING RIFAMPIN-BASED TB THERAPY Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-05T19:07:00.000+02:00",
    "crawled": "2018-03-05T19:36:29.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "glaxosmithkline",
        "plc",
        "glaxosmithkline",
        "plc",
        "viiv",
        "healthcare",
        "announces",
        "positive",
        "new",
        "dolutegravir",
        "data",
        "treatment",
        "people",
        "living",
        "hiv",
        "tuberculosis",
        "glaxosmithkline",
        "plc",
        "dolutegravir",
        "administered",
        "50mg",
        "dual",
        "nucleoside",
        "reverse",
        "transcriptase",
        "inhibitor",
        "effective",
        "glaxosmithkline",
        "plc",
        "dolutegravir",
        "adult",
        "receiving",
        "tb",
        "therapy",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}